Revenue Growth Driven by Top-Line Expansion
Total revenue increased 6.3% year-over-year to $3.37B in Q1 2026, up from $3.17B in Q1 2025, indicating solid demand across Henry Schein's dental and medical distribution segments.
HENRY SCHEIN INC is expected to release its Q2 2026 10-Q filing in the upcoming earnings season. Last quarter: Henry Schein (HSIC) delivered 6.3% revenue growth to $3.37B in Q1 2026, but net income declined 2.7% to $107M as SG&A expenses surged 9.6% and operating cash flow turned sharply negative at -$97M.
Drawn from management commentary in the Q1 2026 10-Q:
Total revenue increased 6.3% year-over-year to $3.37B in Q1 2026, up from $3.17B in Q1 2025, indicating solid demand across Henry Schein's dental and medical distribution segments.
Selling, General & Administrative expenses rose 9.6% YoY to $809M, outpacing revenue growth of 6.3% and gross profit growth of 7.0%, compressing the operating margin slightly from 5.52% to 5.40%.
Gross margin held relatively steady at 31.77%, a modest improvement from 31.57% in the prior year period, suggesting the company maintained pricing discipline despite a 6.0% rise in cost of revenue to $2.30B.
Revenue
$3.37B
++6.31% YoY
EPS (Basic)
$0.93
++4.49% YoY
Gross Margin
31.8%
++0.20% YoY
Operating Income
$182M
++4.00% YoY
Add HSIC to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.